The convergence of psychedelic research and anti-aging therapies reveals a novel approach to enhancing mental health and longevity. As synthetic lysergamides like 1P-LSD emerge, their potential to alter neurobiology and promote resilience against age-related decline becomes increasingly relevant. Metformin’s established role in modulating metabolic processes further complements this investigation, suggesting a multidimensional strategy for health optimization. By leveraging insights from both psychedelic compounds and well-studied metabolic drugs, researchers could create integrated therapies that not only address mental well-being but also extend healthy lifespan.
